Literature DB >> 27646950

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

Philip W Kantoff1, James L Gulley1, Cesar Pico-Navarro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27646950      PMCID： PMC6411419          DOI： 10.1200/JCO.2016.69.7748

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
  1 in total
  24 in total

Review 1.  Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.

Authors:  Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au
Journal:  Breast Care (Basel)       Date:  2018-01-31       Impact factor: 2.860

Review 2.  Immunotherapy of Prostate Cancer: Facts and Hopes.

Authors:  Marijo Bilusic; Ravi A Madan; James L Gulley
Journal:  Clin Cancer Res       Date:  2017-06-29       Impact factor: 12.531

Review 3.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

Review 4.  Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.

Authors:  Ariel E Marciscano; Ravi A Madan
Journal:  Curr Treat Options Oncol       Date:  2018-03-08

5.  Bispecific protein targets prostate cancer.

Authors:  Antony W Burgess
Journal:  Oncotarget       Date:  2017-05-30

Review 6.  [Immunotherapy for the treatment of prostate cancer-a comeback?]

Authors:  M De Santis
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

Review 7.  Novel tumour antigens and the development of optimal vaccine design.

Authors:  Victoria A Brentville; Suha Atabani; Katherine Cook; Lindy G Durrant
Journal:  Ther Adv Vaccines Immunother       Date:  2018-04-10

Review 8.  Prostate cancer.

Authors:  Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow
Journal:  Nat Rev Dis Primers       Date:  2021-02-04       Impact factor: 52.329

Review 9.  The potential of CAR T cell therapy for prostate cancer.

Authors:  Philipp Wolf; Jamal Alzubi; Christian Gratzke; Toni Cathomen
Journal:  Nat Rev Urol       Date:  2021-07-08       Impact factor: 14.432

Review 10.  Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.

Authors:  Ban Qi Tay; Quentin Wright; Rahul Ladwa; Christopher Perry; Graham Leggatt; Fiona Simpson; James W Wells; Benedict J Panizza; Ian H Frazer; Jazmina L G Cruz
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.